ID27825A - Sediaan lepas lambat - Google Patents

Sediaan lepas lambat

Info

Publication number: ID27825A
Authority: ID; Indonesia
Prior art keywords: ready; slow
Prior art date: 1998-03-26

Application number

IDW20002175A

Other languages

English (en)

Indonesian (id)

Inventor

Kazunari Yamashita

Eiji Hashimoto

Yukihiro Nomura

Fumio Shimojo

Shigeki Tamura

Takeo Hirose

Satoshi Ueda

Takashi Saitoh

Rinta Ibuki

Toshio Ideno

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-26

Filing date

1999-03-25

Publication date

2001-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26420115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-25 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2001-04-26 Publication of ID27825A publication Critical patent/ID27825A/id

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Inorganic Chemistry (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrane Compounds (AREA)

IDW20002175A 1998-03-26 1999-03-25 Sediaan lepas lambat ID27825A (id)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP7903998		1998-03-26
JP18296398		1998-06-29

Publications (1)

Publication Number	Publication Date
ID27825A true ID27825A (id)	2001-04-26

Family

ID=26420115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW20002175A ID27825A (id)	1998-03-26	1999-03-25	Sediaan lepas lambat

Country Status (31)

Country	Link
US (5)	US6440458B1 (pl)
EP (3)	EP2198858B1 (pl)
JP (4)	JP3714970B2 (pl)
KR (3)	KR100505464B1 (pl)
CN (1)	CN1229111C (pl)
AR (1)	AR023299A1 (pl)
AT (3)	ATE464900T1 (pl)
AU (1)	AU749623B2 (pl)
BR (1)	BRPI9909201B8 (pl)
CA (1)	CA2322516C (pl)
CZ (1)	CZ300548B6 (pl)
DE (2)	DE69918074T2 (pl)
DK (3)	DK1064942T3 (pl)
ES (3)	ES2367294T3 (pl)
HR (1)	HRP20000707B1 (pl)
HU (1)	HU230889B1 (pl)
ID (1)	ID27825A (pl)
IL (1)	IL138466A (pl)
ME (2)	MEP30008A (pl)
NO (1)	NO330578B1 (pl)
NZ (1)	NZ507211A (pl)
PL (1)	PL193244B1 (pl)
PT (3)	PT2198858E (pl)
RS (1)	RS50164B (pl)
RU (1)	RU2214244C9 (pl)
SI (1)	SI1064942T1 (pl)
SK (1)	SK286887B6 (pl)
TR (1)	TR200002771T2 (pl)
TW (2)	TWI235068B (pl)
WO (1)	WO1999049863A1 (pl)
ZA (1)	ZA200004963B (pl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US7399480B2 (en) *	1997-09-26	2008-07-15	Abbott Laboratories	Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en)	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
DK1064942T3 (da) *	1998-03-26	2004-11-01	Fujisawa Pharmaceutical Co	Sustained release-fremstilling af et makrolid
US7455853B2 (en) *	1998-09-24	2008-11-25	Abbott Cardiovascular Systems Inc.	Medical devices containing rapamycin analogs
US6855172B2 (en)	1998-10-13	2005-02-15	Dry, Inc.	Dry-cleaning article, composition and methods
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
WO2001066081A2 (de) *	2000-03-08	2001-09-13	Awd.Pharma Gmbh & Co.Kg	Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
PT1296651E (pt)	2000-06-27	2008-02-12	Vectura Ltd	Método para fazer partículas para serem usadas numa composição farmacêutica
CA2413692C (en) *	2000-06-27	2011-10-18	Vectura Limited	Method of making particles for use in a pharmaceutical composition
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
PL409579A1 (pl)	2001-02-19	2015-03-02	Novartis Ag	Leczenie raka
ES2376739T3 (es)	2001-03-27	2012-03-16	Galectin Therapeutics Inc.	Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US6645946B1 (en)	2001-03-27	2003-11-11	Pro-Pharmaceuticals, Inc.	Delivery of a therapeutic agent in a formulation for reduced toxicity
GB0108498D0 (en) *	2001-04-04	2001-05-23	Novartis Ag	Organic Compounds
JP2005512946A (ja) *	2001-05-09	2005-05-12	ノバルティスアクチエンゲゼルシャフト	選択的免疫調節法
AUPR529701A0 (en) *	2001-05-28	2001-06-21	Fujisawa Pharmaceutical Co., Ltd.	Pharmaceutical composition
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
CA2465405A1 (en)	2001-11-02	2003-05-08	Wockhardt Limited	Controlled release compositions for macrolide antimicrobial agents
JP2003327536A (ja) *	2002-03-07	2003-11-19	Kitasato Inst:The	ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
EP2263709A1 (en) *	2002-09-06	2010-12-22	Abbott Laboratories	Medical device having hydration inhibitor
ES2552682T3 (es)	2003-03-10	2015-12-01	Merck Sharp & Dohme Corp.	Agentes antibacterianos novedosos
US20040185009A1 (en) *	2003-03-19	2004-09-23	Dexcel Pharma Technologies Ltd.	Composition and device for treating periodontal diseases
US7645876B2 (en) *	2004-12-01	2010-01-12	TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság	Processes for producing crystalline macrolides
GB0307866D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
GB0307867D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US7476403B2 (en) *	2003-06-16	2009-01-13	Andrx Pharmaceuticals, Llc	Oral extended-release composition
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
CN1819817A (zh) *	2003-07-09	2006-08-16	株式会社钟根堂	一种泰克利玛的固体分散体
US20050043272A1 (en) *	2003-07-11	2005-02-24	Pro-Pharmaceuticals, Inc.	Compositions and methods for hydrophobic drug delivery
US8591946B2 (en)	2003-08-29	2013-11-26	Veloxis Pharmaceuticals A/S	Modified release compositions comprising tacrolimus
DE602004028023D1 (de) *	2003-08-29	2010-08-19	Lifecycle Pharma As	Tacrolimus enthaltende feste dispersionen
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1675576A1 (en) *	2003-10-03	2006-07-05	LifeCycle Pharma A/S	A method for preparing modified release pharmaceutical compositions
US7285544B2 (en) *	2003-11-18	2007-10-23	Bernstein Eric F	Use of nitroxides in treating skin disease
CA2552305A1 (en) *	2003-12-30	2005-07-14	Astellas Pharma Inc.	Use of macrolides for treating or preventing airflow obstruction
KR100485877B1 (ko) *	2003-12-30	2005-04-28	종근당바이오 주식회사	타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
WO2005079314A2 (en) *	2004-02-13	2005-09-01	Pro-Pharmaceuticals, Inc.	Compositions and methods used to treat acne and candida
EP1773128A2 (en) *	2004-08-02	2007-04-18	Pro-Pharmaceuticals, Inc.	Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006021443A2 (en) *	2004-08-26	2006-03-02	Novartis Ag	Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
US20060094744A1 (en) *	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
MX2007006119A (es) *	2005-01-05	2007-07-19	Teva Gyogyszergyar Zartkoruen	Tacrolimus amorfo y preparacion de el.
KR100678824B1 (ko) *	2005-02-04	2007-02-05	한미약품 주식회사	용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
US20060210638A1 (en) *	2005-03-17	2006-09-21	Elan Pharma International Limited	Injectable compositions of nanoparticulate immunosuppressive compounds
CN101410098B (zh) *	2006-01-23	2012-01-18	耶路撒冷希伯来大学伊森姆研究发展公司	包括含亲脂性药物的纳米胶囊的微球
HUP0600097A3 (en) *	2006-02-08	2008-07-28	Richter Gedeon Nyrt	Pharmaceutical compositions comprising tacrolimus and process for their preparation
JP2007308479A (ja)	2006-04-20	2007-11-29	Shin Etsu Chem Co Ltd	固体分散体製剤
EP2067475A4 (en) *	2006-09-26	2010-12-15	Astellas Pharma Inc	PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
EP1938804A1 (en) *	2006-12-22	2008-07-02	Novartis AG	Pharmaceutical formulation comprising neurokinin antagonist
WO2008081829A1 (ja) *	2006-12-27	2008-07-10	Astellas Pharma Inc.	難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
US7521523B2 (en)	2006-12-28	2009-04-21	Eastman Chemical Company	Oxygen-scavenging polyester compositions useful in packaging
WO2008084698A1 (ja)	2006-12-28	2008-07-17	Astellas Pharma Inc.	タクロリムス徐放性医薬組成物
CN101573109A (zh) *	2006-12-28	2009-11-04	利默里克生物制药公司	用于治疗的方法和组合物
CA2678455C (en) *	2007-01-10	2019-02-12	Board Of Regents The University Of Texas System	Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US20100086592A1 (en) *	2007-03-29	2010-04-08	Panacea Biotec Limited.	Modified dosage forms of tacrolimus
ITMI20070720A1 (it) *	2007-04-06	2008-10-07	Monteresearch Srl	Composizioni orali contenenti tacrolimus in forma amorfa
WO2008135828A2 (en)	2007-05-03	2008-11-13	Pfizer Products Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en)	2007-05-03	2008-11-13	Pfizer Products Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
SI2167033T1 (sl)	2007-05-30	2017-08-31	Veloxis Pharmaceuticals A/S	Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
US12083103B2 (en)	2007-05-30	2024-09-10	Veloxis Pharmaceuticals, Inc.	Tacrolimus for improved treatment of transplant patients
US9545384B2 (en)	2007-06-04	2017-01-17	Bend Research, Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en)	2007-06-04	2016-05-04	Bend Research, Inc	Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
EP2182957A4 (en) *	2007-07-31	2012-07-18	Limerick Biopharma Inc	PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
SI2200588T1 (sl)	2007-09-25	2019-08-30	Solubest Ltd.	Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
CN105732745A (zh)	2007-10-25	2016-07-06	森普拉制药公司	大环内酯类抗菌剂的制备方法
TW200932240A (en)	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR20090044269A (ko) *	2007-10-31	2009-05-07	(주)아모레퍼시픽	서방성 나노입자 및 이를 함유하는 화장료 조성물
WO2009073215A1 (en)	2007-12-06	2009-06-11	Bend Research, Inc.	Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en)	2007-12-06	2016-01-12	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
CL2008000374A1 (es) *	2008-02-05	2008-04-04	Igloo Zone Chile S A	Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US8222272B2 (en) *	2008-04-11	2012-07-17	Roxane Laboratories, Inc.	Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US9549918B2 (en) *	2008-05-30	2017-01-24	Veloxis Pharmaceuticals A/S	Stabilized tacrolimus composition
US12403095B2 (en)	2008-05-30	2025-09-02	Veloxis Pharmaceuticals, Inc.	Stabilized tacrolimus composition
WO2010004304A1 (en) *	2008-06-17	2010-01-14	Biotica Technology Limited	Novel compounds and methods for their production
AU2009308182B2 (en)	2008-10-24	2016-05-19	Cempra Pharmaceuticals, Inc.	Biodefenses using triazole-containing macrolides
EP2448406B1 (en)	2009-02-26	2016-04-20	Relmada Therapeutics, Inc.	Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
US9480679B2 (en)	2009-09-10	2016-11-01	Cempra Pharmaceuticals, Inc.	Methods for treating malaria, tuberculosis and MAC diseases
EP2541716A1 (en)	2010-02-25	2013-01-02	Panasonic Corporation	Demand and supply control apparatus, demand and supply control method, and program
JP5823484B2 (ja)	2010-07-14	2015-11-25	千寿製薬株式会社	α―ケトアミド誘導体固体分散体
MA34586B1 (fr) *	2010-08-25	2013-10-02	Medis Lab	Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
EP2613630A4 (en)	2010-09-10	2014-01-15	Cempra Pharmaceuticals Inc	HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
WO2013025449A1 (en) *	2011-08-16	2013-02-21	Merck Sharp & Dohme Corp.	Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
JP6368242B2 (ja) *	2011-10-06	2018-08-01	ノバルティスアーゲー	４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
MX2014011537A (es)	2012-03-27	2015-02-10	Cempra Pharmaceuticals Inc	Formulaciones parenterales para la administracion de antibioticos macrolidos.
EP2871188B1 (en) *	2012-07-06	2017-04-19	Godo Shusei Co., Ltd.	Method for separating cyclic macrolide compound
HK1217665A1 (zh)	2013-03-14	2017-01-20	森普拉制药公司	用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru)	2013-03-15	2017-04-24	Семпра Фармасьютикалс, Инк.	Конвергентные способы получения макролидных антибактериальных агентов
US9168246B2 (en)	2013-06-27	2015-10-27	Veloxis Pharmaceutical A/S	Regimen for suppressing organ rejection
CN103432099A (zh) *	2013-08-13	2013-12-11	江苏正大清江制药有限公司	一种他克莫司缓释胶囊及其制备方法
WO2016078481A1 (zh)	2014-11-21	2016-05-26	杭州领业医药科技有限公司	一种含他克莫司的药物组合物及其制备方法
CN104473907A (zh) *	2014-12-25	2015-04-01	北京华禧联合科技发展有限公司	一种他克莫司的口服缓释制剂
HK1245095A1 (zh)	2015-05-20	2018-08-24	Novartis Ag	依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CN104840446B (zh) *	2015-05-27	2017-08-11	福建科瑞药业有限公司	一种他克莫司药物组合物及其制备方法
PL3443012T3 (pl)	2016-04-15	2026-04-20	Bioatla, Inc.	Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania
EP3509572A4 (en) *	2016-09-08	2020-05-13	Synergistic Therapeutics, LLC	TOPICAL FORMULATION FOR HAIR GROWTH
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
KR102081176B1 (ko) *	2018-06-22	2020-02-25	주식회사 종근당	타크로리무스를 포함하는 서방형 약제학적 제제
US20220062305A1 (en) *	2018-12-18	2022-03-03	DDP Specialty Electronic Materials US, Inc.	Sustained release composition comprising an ethylcellulose
AU2020234718A1 (en)	2019-03-13	2023-05-18	Tearsolutions, Inc.	Compositions and methods for promoting islet viability and enhancing insulin secretion
GR1009790B (el)	2019-03-20	2020-08-03	Φαρματεν Α.Β.Ε.Ε.	Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
JP7681303B2 (ja) *	2021-09-03	2025-05-22	国立研究開発法人農業・食品産業技術総合研究機構	養分供給量推定方法、養分供給体の利用方法、プログラム、および推定システム

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL32929A (en)	1968-09-03	1973-08-29	Banker G	Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug
US4127647A (en) *	1975-04-08	1978-11-28	Meiji Seika Kaisha, Ltd.	Process for preparation of stable amorphous macrolide antibiotic solids
US4389393A (en)	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPS62208103A (ja)	1986-03-07	1987-09-12	Yokogawa Hewlett Packard Ltd	ロボツト運動制御システム
GB8608080D0 (en)	1986-04-02	1986-05-08	Fujisawa Pharmaceutical Co	Solid dispersion composition
JPS63150220A (ja) *	1986-12-15	1988-06-22	Dainippon Pharmaceut Co Ltd	経口用固形製剤の製造方法
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
JP2822389B2 (ja)	1987-06-05	1998-11-11	藤沢薬品工業株式会社	抗ｆｒ−９００５０６物質抗体、および高感度酵素免疫測定法
ATE120466T1 (de)	1987-12-09	1995-04-15	Fisons Plc	Makrozyklische verbindungen.
DE3742525C2 (de)	1987-12-11	1998-02-19	Hertz Inst Heinrich	Verfahren zur Herstellung von Metallalkylverbindungen und deren Verwendung
FR2624732B1 (fr) *	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
JPH02232814A (ja)	1989-03-07	1990-09-14	Fuji Photo Film Co Ltd	磁気記録媒体
ES2066915T3 (es) *	1989-07-05	1995-03-16	Fujisawa Pharmaceutical Co	Composicion liquida acuosa para uso externo.
KR0159766B1 (ko)	1989-10-16	1998-12-01	후지사와 토모키치로	양모제 조성물
DK0427680T3 (da)	1989-11-09	1995-12-18	Sandoz Ltd	Heteroatom-holdige cykliske forbindelser
JPH03232814A (ja) *	1990-02-08	1991-10-16	Shin Etsu Chem Co Ltd	徐放性錠剤の製造方法
EP0594600A1 (en)	1990-03-13	1994-05-04	FISONS plc	Immunosuppressive macrocyclic compounds
US5643901A (en)	1990-06-11	1997-07-01	Fujisawa Pharmaceutical Co., Ltd.	Medicament for treating idiopathic thrombocytopenic purpura
JPH05507915A (ja)	1990-06-11	1993-11-11	藤沢薬品工業株式会社	特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en)	1990-07-02	1998-05-30	Novartis Ag	Heteroatoms-containing tricyclic compounds.
EP0480623A1 (en)	1990-10-11	1992-04-15	Merck & Co. Inc.	New halomacrolides and derivatives having immunosuppressive activity
US5252732A (en)	1991-09-09	1993-10-12	Merck & Co., Inc.	D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en)	1991-09-09	1993-05-04	Merck & Co., Inc.	N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en)	1991-09-09	1993-09-21	Merck & Co., Inc.	Imidazolidyl macrolides having immunosuppressive activity
JP3128320B2 (ja)	1992-03-28	2001-01-29	株式会社常盤電機	不燃性シート及びその製造方法
GB9208492D0 (en) *	1992-04-16	1992-06-03	Glaxo Spa	Heterocyclic compounds
HUT66531A (en)	1992-05-07	1994-12-28	Sandoz Ag	Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9209882D0 (en) *	1992-05-07	1992-06-24	Glaxo Lab Sa	Compositions
JP2707023B2 (ja) *	1992-07-01	1998-01-28	株式会社大塚製薬工場	経口吸収用製剤
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
AU686115B2 (en)	1992-11-02	1998-02-05	Fujisawa Pharmaceutical Co., Ltd.	Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
JP3520517B2 (ja) *	1992-11-18	2004-04-19	藤沢薬品工業株式会社	医薬用持続性製剤
MY110603A (en)	1993-05-27	1998-08-29	Novartis Ag	Tetrahydropyran derivatives
DE4329503A1 (de) *	1993-09-01	1995-03-02	Galenik Labor Freiburg Gmbh	Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) *	1993-09-01	2001-03-20	Novatis Ag	Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
JP3232814B2 (ja)	1993-09-22	2001-11-26	ジェイエスアール株式会社	感熱記録媒体用インキ組成物
EP0758244B2 (en) *	1994-05-06	2008-02-13	Pfizer Inc.	Controlled-release dosage forms of azithromycin
AR004480A1 (es)	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
BE1009856A5 (fr) *	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CA2229718A1 (en) *	1995-08-24	1997-03-06	David J. Mathre	Process for the preparation of imidazolyl macrolide immunosuppressants
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
ZA9710927B (en)	1996-12-06	1998-06-15	Fujisawa Pharmaceutical Co	Pharmaceutical composition.
DK1064942T3 (da) *	1998-03-26	2004-11-01	Fujisawa Pharmaceutical Co	Sustained release-fremstilling af et makrolid

1999
- 1999-03-25 DK DK99909332T patent/DK1064942T3/da active
- 1999-03-25 ES ES10152774T patent/ES2367294T3/es not_active Expired - Lifetime
- 1999-03-25 IL IL13846699A patent/IL138466A/xx not_active IP Right Cessation
- 1999-03-25 TW TW092115044A patent/TWI235068B/zh not_active IP Right Cessation
- 1999-03-25 DE DE69918074T patent/DE69918074T2/de not_active Expired - Lifetime
- 1999-03-25 ME MEP-300/08A patent/MEP30008A/xx unknown
- 1999-03-25 US US09/403,787 patent/US6440458B1/en not_active Expired - Lifetime
- 1999-03-25 CN CNB998064157A patent/CN1229111C/zh not_active Expired - Lifetime
- 1999-03-25 KR KR10-2003-7005713A patent/KR100505464B1/ko not_active Expired - Lifetime
- 1999-03-25 AT AT04002277T patent/ATE464900T1/de active
- 1999-03-25 BR BRPI9909201A patent/BRPI9909201B8/pt not_active IP Right Cessation
- 1999-03-25 DE DE69942286T patent/DE69942286D1/de not_active Expired - Lifetime
- 1999-03-25 ES ES99909332T patent/ES2219000T3/es not_active Expired - Lifetime
- 1999-03-25 CZ CZ20003549A patent/CZ300548B6/cs not_active IP Right Cessation
- 1999-03-25 EP EP10152774A patent/EP2198858B1/en not_active Expired - Lifetime
- 1999-03-25 ME MEP-2008-300A patent/ME00189B/me unknown
- 1999-03-25 NZ NZ507211A patent/NZ507211A/en not_active IP Right Cessation
- 1999-03-25 AT AT99909332T patent/ATE269075T1/de active
- 1999-03-25 KR KR10-2000-7010438A patent/KR100440553B1/ko not_active Expired - Lifetime
- 1999-03-25 PT PT10152774T patent/PT2198858E/pt unknown
- 1999-03-25 KR KR10-2003-7016882A patent/KR100498765B1/ko not_active Expired - Lifetime
- 1999-03-25 RU RU2000126836A patent/RU2214244C9/ru active Protection Beyond IP Right Term
- 1999-03-25 AT AT10152774T patent/ATE514419T1/de active
- 1999-03-25 DK DK10152774.5T patent/DK2198858T3/da active
- 1999-03-25 TW TW088104712A patent/TW570814B/zh not_active IP Right Cessation
- 1999-03-25 HR HR20000707A patent/HRP20000707B1/xx not_active IP Right Cessation
- 1999-03-25 SK SK1439-2000A patent/SK286887B6/sk not_active IP Right Cessation
- 1999-03-25 TR TR2000/02771T patent/TR200002771T2/xx unknown
- 1999-03-25 ID IDW20002175A patent/ID27825A/id unknown
- 1999-03-25 PT PT99909332T patent/PT1064942E/pt unknown
- 1999-03-25 EP EP04002277A patent/EP1421939B9/en not_active Revoked
- 1999-03-25 CA CA2322516A patent/CA2322516C/en not_active Expired - Lifetime
- 1999-03-25 DK DK04002277.4T patent/DK1421939T5/da active
- 1999-03-25 PL PL343096A patent/PL193244B1/pl unknown
- 1999-03-25 PT PT04002277T patent/PT1421939E/pt unknown
- 1999-03-25 ES ES04002277T patent/ES2343248T3/es not_active Expired - Lifetime
- 1999-03-25 WO PCT/JP1999/001499 patent/WO1999049863A1/ja not_active Ceased
- 1999-03-25 EP EP99909332A patent/EP1064942B9/en not_active Expired - Lifetime
- 1999-03-25 AU AU28563/99A patent/AU749623B2/en not_active Expired
- 1999-03-25 JP JP54564199A patent/JP3714970B2/ja not_active Expired - Lifetime
- 1999-03-25 SI SI9930622T patent/SI1064942T1/xx unknown
- 1999-03-25 RS YUP-580/00A patent/RS50164B/sr unknown
- 1999-03-25 HU HU0101237A patent/HU230889B1/hu unknown
- 1999-03-26 AR ARP990101353A patent/AR023299A1/es active IP Right Grant
2000
- 2000-09-18 ZA ZA200004963A patent/ZA200004963B/en unknown
- 2000-09-25 NO NO20004773A patent/NO330578B1/no not_active IP Right Cessation
2001
- 2001-10-17 US US09/978,025 patent/US6576259B2/en not_active Expired - Lifetime
2003
- 2003-04-14 US US10/412,281 patent/US6884433B2/en not_active Expired - Lifetime
2004
- 2004-08-18 JP JP2004237947A patent/JP4622382B2/ja not_active Expired - Lifetime
- 2004-08-18 JP JP2004237946A patent/JP3992031B2/ja not_active Expired - Lifetime
2005
- 2005-02-17 US US11/059,439 patent/US20050169993A1/en not_active Abandoned
2008
- 2008-07-17 JP JP2008186587A patent/JP4992845B2/ja not_active Expired - Lifetime
- 2008-11-05 US US12/265,108 patent/US8551522B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8551522B2 (en)	2013-10-08
EP1421939B1 (en)	2010-04-21
CN1229111C (zh)	2005-11-30
US20020044967A1 (en)	2002-04-18
DK1421939T3 (da)	2010-08-09
EP1064942B1 (en)	2004-06-16
TWI235068B (en)	2005-07-01
EP1421939A1 (en)	2004-05-26
AU749623B2 (en)	2002-06-27
DK2198858T3 (da)	2011-10-03
BRPI9909201B1 (pt)	2019-04-02
ME00189B (me)	2011-02-10
US6440458B1 (en)	2002-08-27
EP1064942B9 (en)	2011-03-02
CN1301157A (zh)	2001-06-27
CZ300548B6 (cs)	2009-06-10
NZ507211A (en)	2003-07-25
IL138466A (en)	2005-11-20
YU58000A (sh)	2003-08-29
PT1064942E (pt)	2004-10-29
HRP20000707B1 (en)	2005-06-30
TW570814B (en)	2004-01-11
PL193244B1 (pl)	2007-01-31
DE69942286D1 (de)	2010-06-02
DE69918074T2 (de)	2004-11-04
DE69918074D1 (de)	2004-07-22
ZA200004963B (en)	2002-03-27
ATE269075T1 (de)	2004-07-15
DK1421939T5 (da)	2011-07-18
NO330578B1 (no)	2011-05-16
JP4992845B2 (ja)	2012-08-08
ATE464900T1 (de)	2010-05-15
ES2367294T3 (es)	2011-11-02
HUP0101237A3 (en)	2002-06-28
JP2009007369A (ja)	2009-01-15
ES2343248T3 (es)	2010-07-27
JP2004352727A (ja)	2004-12-16
EP1421939B9 (en)	2011-03-02
MEP30008A (en)	2010-10-10
AR023299A1 (es)	2002-09-04
BRPI9909201B8 (pt)	2021-05-25
US6576259B2 (en)	2003-06-10
SK286887B6 (sk)	2009-07-06
US6884433B2 (en)	2005-04-26
PL343096A1 (en)	2001-07-30
KR100440553B1 (ko)	2004-07-15
US20090074858A1 (en)	2009-03-19
JP3714970B2 (ja)	2005-11-09
NO20004773L (no)	2000-11-23
CA2322516A1 (en)	1999-10-07
DK1064942T3 (da)	2004-11-01
ATE514419T1 (de)	2011-07-15
HRP20000707A2 (en)	2001-12-31
PT2198858E (pt)	2011-09-01
WO1999049863A1 (en)	1999-10-07
RU2214244C9 (ru)	2020-07-29
RS50164B (sr)	2009-05-06
US20030235614A1 (en)	2003-12-25
SK14392000A3 (sk)	2001-03-12
KR20030040556A (ko)	2003-05-22
EP2198858A1 (en)	2010-06-23
HU230889B1 (hu)	2018-12-28
TR200002771T2 (tr)	2001-02-21
JP3992031B2 (ja)	2007-10-17
CA2322516C (en)	2010-10-05
AU2856399A (en)	1999-10-18
EP1064942A1 (en)	2001-01-03
CZ20003549A3 (cs)	2001-04-11
PT1421939E (pt)	2010-07-12
JP2004354394A (ja)	2004-12-16
TW200306867A (en)	2003-12-01
HK1038185A1 (en)	2002-03-08
JP4622382B2 (ja)	2011-02-02
BR9909201A (pt)	2000-11-14
HUP0101237A1 (hu)	2001-09-28
KR20010042083A (ko)	2001-05-25
KR100505464B1 (ko)	2005-08-04
KR20040007751A (ko)	2004-01-24
RU2000126836A (ru)	2002-09-10
US20050169993A1 (en)	2005-08-04
ES2343248T9 (es)	2011-08-23
IL138466A0 (en)	2001-10-31
EP1064942A4 (en)	2002-09-04
NO20004773D0 (no)	2000-09-25
ES2219000T3 (es)	2004-11-16
SI1064942T1 (en)	2004-12-31
KR100498765B1 (ko)	2005-07-01
RU2214244C2 (ru)	2003-10-20
EP2198858B1 (en)	2011-06-29

Publication	Publication Date	Title
ID27825A (id)	2001-04-26	Sediaan lepas lambat
DK1070058T3 (da)	2003-08-18	(4-Arylsulfonylamino)-tetrahydropyran-4-carboxylsyrehydroxamider
DE69829040D1 (de)	2005-03-24	Elektroplattierungschemie
DE69917956D1 (de)	2004-07-22	Tintenzuführsystemadapter
DE69936168D1 (de)	2007-07-12	Mehrfachprobeninlassmassenspektrometer
DE69808145D1 (de)	2002-10-24	Tintenbehälternachfüllsystem
DE69904565D1 (de)	2003-01-30	Hubventilsteuerungseinrichtung
DE69910321D1 (de)	2003-09-18	Funkempfangspeilantennengerät
FI20002715L (fi)	2000-12-11	Kaiuttimet
NO20004432D0 (no)	2000-09-05	Glysintransportinhibitorer
DE59907306D1 (de)	2003-11-13	Fadenchangierung
ID23458A (id)	2000-04-27	Bentuk sediaan nefazodon
EP1124578A4 (en)	2005-01-19	NEW IMMUNOADJUVANTS
DE69937642D1 (de)	2008-01-10	Trimaranstruktur
DE69916308D1 (de)	2004-05-13	Hydroboronationsverfahren
DE69902880D1 (de)	2002-10-17	Resonanzumwandlerschaltung
DE69904766D1 (de)	2003-02-13	Kodenübersetzer
DE69941418D1 (de)	2009-10-29	Ziehvverfahren
DE59901046D1 (de)	2002-05-02	Methylcyclotetradec-5-en-1-one
DE69902306D1 (de)	2002-09-05	Schwellwertventil
DE69912355D1 (de)	2003-12-04	Antioxydationssystem
DE59903616D1 (de)	2003-01-16	Rollenwicklerwalze
PT1076660E (pt)	2002-11-29	(4-bromopirazol-3-il)-benzazolos substituidos
DE69905102D1 (de)	2003-03-06	Spritzgiessmaschinensteuerung
DE69938364D1 (de)	2008-04-24	Polycarbonatabmischung